Skip to content

Depreciation at other companies

Stoke Therapeutics, Inc. logo
Stoke Therapeutics, Inc.STOK
Celcuity logo
CelcuityCELC
Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
Medpace Holdings, Inc. logo
Medpace Holdings, Inc.MEDP
GRAIL, Inc. logo
GRAIL, Inc.GRAL

Other financials

Income statement

See full
Operating income-$39.6M-21.1%
Net income-$35.8M-19.1%
EPS (diluted)-$0.34+19.0%

Balance sheet

See full
Cash & equivalents$56.4M+14.3%
Total debt$3.3M+2.6%
Total equity$415.6M+89.1%
Total assets$436.8M+79.8%

Cash flow

See full
Operating cash flow-$32.4M+0.3%
CapEx$2.0K-99.5%
Free cash flow-$32.4M+1.5%

Valuation

See full
Market cap$976.17M+23.0%
Enterprise value$923.07M+23.5%

Returns & leverage

See full
Return on equity-42.6%-4.6pp
Debt / equity0.0×
Current ratio16.3×+4.3×

Where this comes from

Reported directly by Oric Pharmaceuticals, Inc. in its filing.

Tagged under the XBRL concept us-gaap:Depreciation.

The official record: Oric Pharmaceuticals, Inc.’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about Oric Pharmaceuticals, Inc.'s depreciation.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Oric Pharmaceuticals, Inc.'s depreciation?
Oric Pharmaceuticals, Inc. (ORIC) reported depreciation of $270K in Q1 2026.
How has Oric Pharmaceuticals, Inc.'s depreciation changed year-over-year?
Oric Pharmaceuticals, Inc.'s depreciation decreased by 10.6% year-over-year, from $302K to $270K.
What is the long-term trend for Oric Pharmaceuticals, Inc.'s depreciation?
Over 4 years (2021 to 2025), Oric Pharmaceuticals, Inc.'s depreciation has grown at a 8.0% compound annual growth rate (CAGR), from $897K to $1.22M.